Prof David R. Liu, Professor at Harvard University, the Broad Institute, and HHMI was interviewed by the Sheeky Science Show. In the interview, they discussed how to make precise genome editing safe & efficient using the latest CRISPR tech advances in base editing and prime editing and taking it to the clinic (e.g Beam Therapeutics). They talked about the next frontier, epigenome editing.
There are currently two major ways to deliver CRISPR gene therapies into the human body. There is the AAD virus and the LNP (lipid nanoparticle). There are hundreds of different AAD virus and lipid nanoparticles. Verve Therapeutics and Beam Therapeutics used LNP to deliver gene therapy into primates to reduce cholesterol. There will be a large library of nanoparticles and viruses used for delivering gene therapy.
Jonathan Weissman and David Liu have formed a startup, Chroma Medicine, to use CRISPR-Cas9 and perform programmable epigenome editing.
DRL is a co-founder and consultant for Beam Therapeutics, Prime Medicine, Pairwise Plants, Exo Therapeutics, and Chroma Medicine.
SOURCES- UCSF, Verve Therapeutix, Sheeky Science show, Dr David Liu
Written by Brian Wang, Nextbigfuture.com
Brian Wang is a Futurist Thought Leader and a popular Science blogger with 1 million readers per month. His blog Nextbigfuture.com is ranked #1 Science News Blog. It covers many disruptive technology and trends including Space, Robotics, Artificial Intelligence, Medicine, Anti-aging Biotechnology, and Nanotechnology.
Known for identifying cutting edge technologies, he is currently a Co-Founder of a startup and fundraiser for high potential early-stage companies. He is the Head of Research for Allocations for deep technology investments and an Angel Investor at Space Angels.
A frequent speaker at corporations, he has been a TEDx speaker, a Singularity University speaker and guest at numerous interviews for radio and podcasts. He is open to public speaking and advising engagements.